Sign In
Buy KNBIF
$0.0202
+0 (+0%)
At Close: Jul 31, 2026
Kane Biotech Announces Third Quarter 2025 Financial Results
07:25am, Friday, 28'th Nov 2025
WINNIPEG, Manitoba, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announced its third quarter 2025 financial results.
Kane Biotech Announces New Private Placement Offering
07:25am, Thursday, 27'th Nov 2025
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane�
Kane Biotech Presents revyve® Data at Diabetic Foot and Southern Region Burn Conferences
07:25am, Tuesday, 04'th Nov 2025
WINNIPEG, Manitoba, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane Biotech” or “Kane”) today announced new clinical and pre-clinical data demonstrating the performance
Kane Biotech Completes U.S. FDA 510(k) Submission for revyve® Antimicrobial Wound Cleanser
05:05pm, Tuesday, 16'th Sep 2025
WINNIPEG, Manitoba, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or the “Company”) today announces that it has completed a U.S. Food and Drug Administration
Kane Biotech Completes Enrollment in U.S. Case Series Studies of its revyve® Antimicrobial Wound Gel and Spray
05:05pm, Wednesday, 10'th Sep 2025
WINNIPEG, Manitoba, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or “Kane”) today announces that it has enrolled 28 participants in its revyve® Antimicrobi
Kane Biotech to Present at Advanced Wound Care Summit USA
05:05pm, Monday, 14'th Jul 2025
WINNIPEG, Manitoba, July 14, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane Biotech” or “Kane”) announces today that Kane Biotech's Interim Chief Executive Officer, Dr. Robert
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, June 26, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane
Kane Biotech Provides Further Corporate Update
05:05pm, Wednesday, 18'th Jun 2025
WINNIPEG, Manitoba, June 18, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) provides updates on its reorganizational phase.
Kane Biotech Announces First Quarter 2025 Financial Results
05:05pm, Thursday, 29'th May 2025
WINNIPEG, Manitoba, May 29, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces its first quarter 2025 financial results.
Kane Biotech Announces Closing of Private Placement Offering and Loan with Insiders of the Company
05:05pm, Monday, 05'th May 2025
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, May 05, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”,
Kane Biotech Announces Fourth Quarter and Full Year 2024 Financial Results, Narrows Strategic Focus and Makes Leadership Change
04:05pm, Monday, 28'th Apr 2025
WINNIPEG, Manitoba, April 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) today announced its fourth quarter and full year
Kane Biotech Announces New Agreement with Outside the Box Capital Inc.
08:00pm, Friday, 11'th Apr 2025
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba,, April 11, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (“Kane Biotech
Kane Biotech Secures IRB Approval to Launch Innovative DispersinB® Acne Trial
08:30am, Thursday, 13'th Mar 2025
Kane to work with the University of Miami to study DispersinB® Acne Cleanser in mild to moderate Acne Vulgaris Kane to work with the University of Miami to study DispersinB® Acne Cleanser in mild to
Kane Biotech Announces Canadian Distribution Agreement With Best Buy Medical for revyve™ Antimicrobial Wound Gel
08:30am, Tuesday, 11'th Mar 2025
Strategic Partnership Expands Access to Innovative Wound Care Solution Across Canada Strategic Partnership Expands Access to Innovative Wound Care Solution Across Canada
Kane Biotech Announces Second and Final Closing of Private Placement Offering
08:30am, Wednesday, 19'th Feb 2025
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”
